Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
Tandem’s Control-IQTM hybrid closed-loop technology now integrates with the 15-day continuous glucose monitoring sensor. This ad will auto-close in 10 seconds ...
This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes. The ...
Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results